Relationship between Age and The Histopathological Features to Chemotherapy Response in Colorectal Cancer Patients: A Prospective Observational Study

Abstract

Introduction Chemotherapy response in early age-onset colorectal cancer patients is still controversial, and the results of chemotherapy response are unknown. Therefore, the purpose of this study is to determine the relationship between the age of colorectal cancer patients and histopathological features and chemotherapy response.

Methods This is a prospective observational study. The subjects in this study were colorectal cancer patients in the Digestive Surgery division at Tertiary Hospital in West Java from September 2021 to September 2022.

Results There were 86 subjects who underwent chemotherapy in accordance with the inclusion and exclusion criteria. Consisting of 39 patients of early age onset and 44 female patients. The most common histopathological feature in early age onset (EAO) and late age onset (LAO) was adenocarcinoma (25% and 46%, respectively). Stage III colorectal cancer affected 38 patients, while stage IV affected 48 patients. There was a significant relationship between early age onset and late age onset with histological features (p < 0.001). The patients with the highest chemotherapy response had stable diseases in EAO (17 patients) and LAO (20 patients). There was no statistically significant relationship between age, histological features, and stage of colorectal cancer and chemotherapy response (p > 0.05). The results of the ordinal logistic regression test showed no systematic relationship between chemotherapy response and age, histopathological features, gender, or cancer stage (p > 0.05).

Conclusion There was no association between age and histopathologic features with chemotherapy response and there is no difference in chemotherapy response between early and late age onset.

Keywords

early-onset - chemotherapy - histopathological features - late-onset

Statements and Declarations

The preparation of this study was supported by internal funding from a Research Grant from Riset Kompetensi Dosen Unpad (RKDU) Faculty of Medicine, Universitas Padjadjaran, with registered number 2203/UN6.3.1/PT.00/2022.

Ethical Declaration

The Dr. Hasan Sadikin Hospital ethics committee approved the study with No. Ethical Approval LB.02.01/X.6.5/351/2022. The Dr. Hasan Sadikin Hospital ethics committee approved the study. Every research participant signed an informed consent form before participating in the study.

Author's Contribution

All authors participated in the conception and design of the study, drafting, and finalizing the manuscript. Kiki Lukman, Gun Gun Gunawan, and Prapanca Nugraha participated in collecting the patient's information. Birgitta M. Dewayani and Etis Primastari participated in the histologic examination of the colorectal diagnosis. Reno Rudiman, Yunia Sribudiani, and Lisa Y. Hasibuan analyzed and interpreted the data.

Data Availability

All data and tables used to support the findings of this study are included within the article and available upon request to the corresponding author.

Publikationsverlauf

Eingereicht: 15. August 2023

Angenommen: 24. Oktober 2023

Artikel online veröffentlicht:
27. November 2023

• References

• 1 Rathore R. MD. Ferri's clinical advisor 2022. Philadelphia: Elsevier; 2022: 426-429
• 2 Siegel RL, Miller KD, Goding Sauer A. et al. Colorectal cancer statistics, 2020. CA Cancer J Clin 2020; 70 (03) 145-164
• 3 National Guidelines for Medical Services in the Management of Colorectal Cancer. Jakarta: Ministry of Health of the Republic of Indonesia; 2018: 35-123
• 4 Quick CR, Biers SM. Essential surgery: problem, diagnosis and management 6th ed. Philadelphia: Elsevier; 2020. 27. 374-386
• 5 Bhanote M, Hicks DG, Dasgupta R. et al. Pathology case report. Philadelphia: Elsevier; 2020. 27. 374-386
• 6 Rudiman R, Lukman K, Barr TI. Correlation Between Tumor Cell Differentiation and CEA Levels in Patients with Adenocarcinoma of the Rectum. Majalah Kedokteran Bandung 2020; 52 (04) 233-237 . Doi: 0.15395/mkb.v52n4.2028
• 7 Leppert BC, Kelly CR. Colorectal Cancer (CRC) - Netter's integrated review of medicine. Philadelphia: Elsevier; 2021. 160. 675-679
• 8 Chua W, Kho PS, Moore MM, Charles KA, Clarke SJ. Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. Crit Rev Oncol Hematol 2011; 79 (03) 224-250
• 9 Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000; 355 (9217) 1745-1750
• 10 Cong Z, Wang D, Cao Y. The relationship between body mass index changes during chemotherapy and prognosis of patients with advanced colorectal cancer: A retrospective cohort study. Medicine (Baltimore) 2018; 97 (22) e10843
• 11 Huang X, Gao P, Song Y. et al. Relationship between circulating tumor cells and tumor response in colorectal cancer patients treated with chemotherapy: a meta-analysis. BMC Cancer 2014; 14: 976
• 12 Sanford NN, Dharwadkar P, Murphy CC. Early-onset colorectal cancer: More than one side to the story. Colorectal Cancer 2020; 9: 28
• 13 Rachmawati M, Yulianti H, Hernowo BS. et al. The Correlation of KRAS Gene Expression and P53 Immunoexpression in Colorectal Adenocarcinoma. Open Access Maced J Med Sci 2019; 7 (12) 1940-1945
• 14 Vandenbroucke JP, von Elm E, Altman DG. et al; STROBE initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med 2007; 147 (08) W163-94
• 15 Cuschieri S. The STROBE guidelines. Saudi J Anaesth 2019; 13 (Suppl. 01) S31-S34
• 16 Georgiou A, Khakoo S, Edwards P. et al. Outcomes of Patients with Early Onset Colorectal Cancer Treated in a UK Specialist Cancer Center. Cancers (Basel) 2019; 11 (10) 1558
• 17 Cercek A, Chatila WK, Yaeger R. et al. A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. J Natl Cancer Inst 2021; 113 (12) 1683-1692
• 18 Sarasqueta C, Perales A, Escobar A. et al; REDISECC-CARESS/CCR group. Impact of age on the use of adjuvant treatments in patients undergoing surgery for colorectal cancer: patients with stage III colon or stage II/III rectal cancer. BMC Cancer 2019; 19 (01) 735
• 19 Abancens M, Bustos V, Harvey H, McBryan J, Harvey BJ. Sexual Dimorphism in Colon Cancer. Front Oncol 2020; 10: 607909
• 20 Chen W, Sun K, Zheng R. et al. Cancer incidence and mortality in China, 2014. Chin J Cancer Res 2018; 30 (01) 1-12
• 21 Ngan RK. Overview of Hong Kong cancer statistics of 2015. Lung 2017; 4 (135) 1
• 22 Cancer Information Service, National Cancer Center Japan. National estimates of cancer incidence based on cancer registries in Japan (1975–2013) Cancer Information Service Web site. Available at: https://ganjoho.jp/en/professional/statistics/table_download.html
• 23 Low EE, Demb J, Liu L. et al. Risk Factors for Early-Onset Colorectal Cancer. Gastroenterology 2020; 159 (02) 492-501.e7
• 24 Wu X, Lin H, Li S. Prognoses of different pathological subtypes of colorectal cancer at different stages: A population-based retrospective cohort study. BMC Gastroenterol 2019; 19 (01) 164
• 25 Li C, Zheng H, Jia H. et al. Prognosis of three histological subtypes of colorectal adenocarcinoma: A retrospective analysis of 8005 Chinese patients. Cancer Med 2019; 8 (07) 3411-3419
• 26 Schwartz LH, Litière S, de Vries E. et al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer 2016; 62: 132-137
• 27 Manjelievskaia J, Brown D, McGlynn KA, Anderson W, Shriver CD, Zhu K. Chemotherapy Use and Survival Among Young and Middle-Aged Patients With Colon Cancer. JAMA Surg 2017; 152 (05) 452-459
• 28 Kneuertz PJ, Chang GJ, Hu CY. et al. Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains. JAMA Surg 2015; 150 (05) 402-409
• 29 Mauri G, Sartore-Bianchi A, Russo AG, Marsoni S, Bardelli A, Siena S. Early-onset colorectal cancer in young individuals. Mol Oncol 2019; 13 (02) 109-131
• 30 Powers BD, Felder SI, Imanirad I, Dessureault S, Dineen SP. The Impact of Histologic Subtype on Receipt of Adjuvant Chemotherapy and Overall Survival in Stage III Colon Cancer: a Retrospective Cohort Analysis. J Gastrointest Cancer 2021; 52 (02) 719-727
• 31 Bong JW, Gim JA, Ju Y. et al. Prognosis and Sensitivity of Adjuvant Chemotherapy in Mucinous Colorectal Adenocarcinoma without Distant Metastasis. Cancers (Basel) 2022; 14 (05) 1297
• 32 Zhang Y, Chen Y, Huang J. et al. Mucinous histology is associated with poor prognosis in locally advanced colorectal adenocarcinoma treated with postoperative first-line adjuvant chemotherapy: A systematic review and meta-analysis. Eur J Surg Oncol 2022; 48 (10) 2075-2081
• 33 Rudiman R, Wijaya A, Sribudiani Y. et al. Identification of KRAS mutation and HER2 expression in Indonesian colorectal cancer population: a cross-sectional study. Ann Med Surg (Lond) 2023; 85 (05) 1761-1768
• 34 Lukman K, Reza AT, Hasibuan LY. et al. Different Clinicopathological Characteristics in Indonesian Colorectal Patients with NRAS Mutations and HER2 Over-Expression. Asian Pac J Cancer Prev 2023; 24 (04) 1373-1377
• 35 Purnama A, Lukman K, Ruchimat T, Rudiman R, Wijaya A, Nugraha P. Vitamin D and Diagnostic Colonoscopy for Colorectal Cancer in Indonesian Population: A Cross-sectional Study. Open Access Maced J Med Sci 2023; 11 (B): 439-445
• 36 O'Sullivan DE, Cheung WY, Boyne DJ. et al. Treatment patterns and survival outcomes of early-onset colorectal cancer patients in Alberta, Canada: a population-based study. Cancer Treat Res Commun 2022; 32: 100585
• 37 Benson AB, Venook AP, Al-Hawary MM. et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2021; 19 (03) 329-359
• 38 Benson AB, Venook AP, Al-Hawary MM. et al. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022; 20 (10) 1139-1167